NuCana (NCNA) vs. Its Rivals Financial Contrast

NuCana (NASDAQ: NCNA) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare NuCana to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, earnings, dividends, profitability and valuation.

Earnings and Valuation

This table compares NuCana and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NuCana N/A N/A N/A
NuCana Competitors $284.28 million $34.29 million 74.13

NuCana’s competitors have higher revenue and earnings than NuCana.

Institutional and Insider Ownership

22.3% of NuCana shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for NuCana and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuCana 0 0 4 0 3.00
NuCana Competitors 852 3200 11603 231 2.71

NuCana presently has a consensus target price of $24.00, suggesting a potential upside of 108.70%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.85%. Given NuCana’s stronger consensus rating and higher probable upside, analysts clearly believe NuCana is more favorable than its competitors.

Profitability

This table compares NuCana and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NuCana N/A N/A N/A
NuCana Competitors -5,312.21% -433.82% -39.43%

Summary

NuCana beats its competitors on 6 of the 10 factors compared.

About NuCana

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply